Revolution Medicines RVMD 深 沪
等待开盘 09-17 09:30:00 美东时间
44.70
-1.500
-3.25%
华盛通- 最 高46.7447
- 今 开46.27
- 成交量 287.13万股
- 最 低 44.60
- 昨 收 46.20
- 总市值 74.67亿
- 52周最高 62.40
- 市盈率 静 --
- 换手率 1.72%
- 52周最低 29.17
- 委 比 86.64%
- 总股本 1.67亿
- 历史最高 62.40
- 量 比 1.08
- 振 幅 4.64%
- 历史最低 14.08
- 每 手 1
- 风险率 6.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
Biggest stock movers Thursday: OPEN, RNA, and more
Stock futures ticked higher Thursday after the S&P 500 and Nasdaq closed at record highs, with investors eagerly awaiting key CPI data. Here are some of Thursday's biggest stock movers: Biggest stock ...
09-11 16:30
Revolution Medicines Reports Promising Phase 1 Study Results
Revolution Medicines ( ($RVMD) ) just unveiled an announcement. On September 10...
09-11 04:37
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
Revolution Medicines announced promising results for daraxonrasib in treating metastatic pancreatic ductal adenocarcinoma (PDAC). Phase 1 data showed strong safety and efficacy in both second-line and first-line patients. For 2L PDAC, the drug demonstrated a confirmed ORR of 35% and 29% for RAS G12X and any RAS mutation, respectively, with median OS of 13.1 and 15.6 months. In 1L PDAC, daraxonrasib monotherapy achieved a 47% ORR and 89% DCR. Comb...
09-10 20:02
Truist Securities Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $99
Truist Securities analyst Asthika Goonewardene initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $99.
09-05 19:59
BD新玩法？百济神州首创9.5亿美元 特许权“变现”模式
8月25日晚间，百济神州（纳斯达克代码：ONC；香港联交所代码：06160.HK；上交所代码：688235.SH）公告与Royalty Pharma达成协议，向...
08-27 07:00
Wells Fargo Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $67
Wells Fargo initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announces Price Target of $67.
08-15 18:57
Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $56
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $57 to $56.
08-07 18:22
Revolution Medicines Q2 EPS $(1.31) Misses $(1.14) Estimate
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(1.14) by 15.01 percent. This is a 61.73 percent decrease over losses of $(0.81) per share
08-07 04:04
